Goldman Sachs Group Inc Dia Medica Therapeutics Inc. Transaction History
Goldman Sachs Group Inc
- $780 Billion
- Q3 2025
A detailed history of Goldman Sachs Group Inc transactions in Dia Medica Therapeutics Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 77,292 shares of DMAC stock, worth $460,660. This represents 0.0% of its overall portfolio holdings.
Number of Shares
77,292
Previous 17,904
331.7%
Holding current value
$460,660
Previous $69,000
668.12%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding DMAC
# of Institutions
81Shares Held
8.02MCall Options Held
19.6KPut Options Held
16.5K-
Israel Englander Millennium Management LLC | New York, Ny1.19MShares$7.08 Million0.0% of portfolio
-
Paragon Associates & Paragon Associates Ii Joint Venture Dallas, TX875KShares$5.22 Million11.8% of portfolio
-
Geode Capital Management, LLC Boston, MA712KShares$4.24 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA665KShares$3.96 Million0.0% of portfolio
-
Morgan Stanley New York, NY580KShares$3.45 Million0.0% of portfolio
About DiaMedica Therapeutics Inc.
- Ticker DMAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,443,100
- Market Cap $158M
- Description
- DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...